Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-125547
Filing Date
2024-11-12
Accepted
2024-11-12 16:36:04
Documents
54
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q xene-20240930.htm   iXBRL 10-Q 2020175
2 EX-31.1 xene-ex31_1.htm EX-31.1 15663
3 EX-31.2 xene-ex31_2.htm EX-31.2 15653
4 EX-32.1 xene-ex32_1.htm EX-32.1 11070
5 EX-32.2 xene-ex32_2.htm EX-32.2 10525
  Complete submission text file 0000950170-24-125547.txt   6194262

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT xene-20240930.xsd EX-101.SCH 675423
57 EXTRACTED XBRL INSTANCE DOCUMENT xene-20240930_htm.xml XML 946780
Mailing Address 200 - 3650 GILMORE WAY BURNABY A1 V5G 48W
Business Address 200 - 3650 GILMORE WAY BURNABY A1 V5G 48W (604) 484-3300
Xenon Pharmaceuticals Inc. (Filer) CIK: 0001582313 (see all company filings)

EIN.: 980661854 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36687 | Film No.: 241449081
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)